Genmab AS (OCSE:GMAB) Margin of Safety % (DCF Earnings Based) : 64.10% (As of May. 06, 2025)

View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2025-05-06), Genmab AS's Predictability Rank is 4-Stars. Genmab AS's intrinsic value calculated from the Discounted Earnings model is kr3981.44 and current share price is kr1429.50. Consequently,

Genmab AS's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 64.10%.

Competitive Comparison of Genmab AS's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Genmab AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Genmab AS's Margin of Safety % (DCF Earnings Based) falls into.

Save Embed

;

Save Embed

;

Genmab AS Margin of Safety % (DCF Earnings Based) Calculation

Genmab AS's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)	=	(Intrinsic Value: DCF (Earnings Based)	-	Current Price)	/	Intrinsic Value: DCF (Earnings Based)
	=	(3981.44	-	1429.50)	/	3981.44
	=	64.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Genmab AS Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Genmab AS's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.